US Pharma MarketingThe post Vesalio’s NATURE trial of enVast achieves primary endpoint appeared first on Medical Device Network.
Vesalio’s NATURE trial of enVast achieves primary endpoint
Vesalio has reported that the NATURE randomised controlled trial of its enVast Coronary Clot Retriever met the primary endpoint. The prospective, multi-centre study enrolled 154 patients at 11 centres. The primary endpoint showed a nearly 26% reduction in infarct size in the enVast group versus standard care. Credit: sasirin pamai/Shutterstock.com. Vesalio has reported that the NATURE randomised controlled trial of its enVast Coronary Clot Retriever met the primary endpoint. The device demonstrated a significant reduction in infarct size for patients with ST-segment elevation myocardial infarction (STEMI) and large thrombus burden (LTB) undergoing primary percutaneous coronary intervention (PCI). Combine business intelligence…
Vesalio has reported that the NATURE randomised controlled trial of its enVast Coronary Clot Retriever met the primary endpoint.
Source: Medical Device Network